Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase I…
Biotechnology
US, Needham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Candel Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | - | -2.011 | - | 0.03 | - | -58 | - | 0.02 | - | 0.02 | - | 1 |
| 2022 | -1.2600 | -0.695 | 0.13 | 0.08 | -36 | -20 | -25 | 0.05 | -24 | 0.05 | 10 | 4 |
| 2023 | -0.0994 | -1.090 | 0.13 | 0.02 | -2 | -31 | -17 | 0.01 | -35 | 0.01 | 14 | 0.81 |
| 2024 | -1.3100 | -1.590 | 0 | 0.02 | -37 | -46 | -37 | 0.01 | -38 | 0.01 | 14 | 0.81 |
| 2025 | - | -1.350 | - | 4 | - | -39 | - | -2 | - | -2 | - | 226 |
| 2026 | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |